

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1599587/magi-farre-publications-by-citations.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

184 papers	6,577 citations	44 h-index	74 g-index
194 ext. papers	7,597 ext. citations	4.9 avg, IF	5.56 L-index

#	Paper	IF	Citations
184	Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 137-44	3.2	324
183	Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. <i>British Journal of Clinical Pharmacology</i> , <b>2000</b> , 49, 104-9	3.8	247
182	Hydroxytyrosol disposition in humans. <i>Clinical Chemistry</i> , <b>2003</b> , 49, 945-52	5.5	241
181	Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>1999</b> , 290, 136-45	4.7	197
180	Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , <b>2005</b> , 78, 1-22	4.9	196
179	Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. <i>Molecular Nutrition and Food Research</i> , <b>2014</b> , 58, 278-88	5.9	182
178	Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2012</b> , 39, 221-6	5.5	177
177	Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 4966-79	3.3	165
176	Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. <i>Journal of Clinical Psychopharmacology</i> , <b>2000</b> , 20, 455-66	1.7	156
175	Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , <b>2016</b> , 15, 801-810	24.1	152
174	Potential role of olive oil phenolic compounds in the prevention of neurodegenerative diseases. <i>Molecules</i> , <b>2015</b> , 20, 4655-80	4.8	143
173	Alcohol and cocaine interactions in humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>1993</b> , 266, 1364-73	4.7	134
172	3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2002</b> , 300, 236-44	4.7	125
171	Pharmacology of MDMA in humans. <i>Annals of the New York Academy of Sciences</i> , <b>2000</b> , 914, 225-37	6.5	115
170	Human Pharmacology of Mephedrone in Comparison with MDMA. <i>Neuropsychopharmacology</i> , <b>2016</b> , 41, 2704-13	8.7	108
169	A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 417-427	59.2	108
168	Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. <i>Psychopharmacology</i> , <b>2004</b> , 173, 364-75	4.7	102

167	MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. <i>Journal of Psychoactive Drugs</i> , <b>2008</b> , 40, 225-36	3.6	90
166	Metabolic disposition and biological significance of simple phenols of dietary origin: hydroxytyrosol and tyrosol. <i>Drug Metabolism Reviews</i> , <b>2016</b> , 48, 218-36	7	90
165	Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. <i>Journal of Analytical Toxicology</i> , <b>2002</b> , 26, 157-65	2.9	88
164	Cocaine and alcohol interactions in humans: neuroendocrine effects and cocaethylene metabolism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>1997</b> , 283, 164-76	4.7	88
163	Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2007</b> , 323, 954-62	4.7	84
162	Salivary Secretory Disorders, Inducing Drugs, and Clinical Management. <i>International Journal of Medical Sciences</i> , <b>2015</b> , 12, 811-24	3.7	75
161	Functional connectivity alterations in brain networks relevant to self-awareness in chronic cannabis users. <i>Journal of Psychiatric Research</i> , <b>2014</b> , 51, 68-78	5.2	74
160	4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 1026-35	4.6	74
159	Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. <i>Journal of Psychopharmacology</i> , <b>2006</b> , 20, 842-9	4.6	74
158	Effect of virgin olive oil and thyme phenolic compounds on blood lipid profile: implications of human gut microbiota. <i>European Journal of Nutrition</i> , <b>2017</b> , 56, 119-131		70
157	Mass spectrometric evaluation of mephedrone in vivo human metabolism: identification of phase I and phase II metabolites, including a novel succinyl conjugate. <i>Drug Metabolism and Disposition</i> , <b>2015</b> , 43, 248-57	4	59
156	Mephedrone Concentrations in Cases of Clinical Intoxication. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 5511-5522	3.3	59
155	Olive Oil Polyphenols Decrease LDL Concentrations and LDL Atherogenicity in Men in a Randomized Controlled Trial. <i>Journal of Nutrition</i> , <b>2015</b> , 145, 1692-7	4.1	58
154	No evidence that MDMA-induced enhancement of emotional empathy is related to peripheral oxytocin levels or 5-HT1a receptor activation. <i>PLoS ONE</i> , <b>2014</b> , 9, e100719	3.7	57
153	Prevalence and risk of gingival enlargement in patients treated with nifedipine. <i>Journal of Periodontology</i> , <b>2001</b> , 72, 605-11	4.6	57
152	Dietary inflammatory index and all-cause mortality in large cohorts: The SUN and PREDIMED studies. <i>Clinical Nutrition</i> , <b>2019</b> , 38, 1221-1231	5.9	55
151	Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. <i>Clinical Pharmacokinetics</i> , <b>2005</b> , 44, 649-60	6.2	53
150	MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?. <i>Frontiers in Genetics</i> , <b>2012</b> , 3, 235	4.5	52

149	Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis. <i>Journal of Psychoactive Drugs</i> , <b>2017</b> , 49, 297-305	3.6	51
148	The hidden web and the fentanyl problem: Detection of ocfentamil as an adulterant in heroin. <i>International Journal of Drug Policy</i> , <b>2017</b> , 40, 78-83	5.5	51
147	Antioxidant activities of hydroxytyrosol main metabolites do not contribute to beneficial health effects after olive oil ingestion. <i>Drug Metabolism and Disposition</i> , <b>2010</b> , 38, 1417-21	4	50
146	Gingival enlargement induced by drugs. <i>Drug Safety</i> , <b>1996</b> , 15, 219-31	5.1	50
145	Dose-dependent metabolic disposition of hydroxytyrosol and formation of mercapturates in rats. <i>Pharmacological Research</i> , <b>2013</b> , 77, 47-56	10.2	46
144	Anomalous brain functional connectivity contributing to poor adaptive behavior in Down syndrome. <i>Cortex</i> , <b>2015</b> , 64, 148-56	3.8	45
143	Conditioned Fear Acquisition and Generalization in Generalized Anxiety Disorder. <i>Behavior Therapy</i> , <b>2015</b> , 46, 627-39	4.8	44
142	A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials. <i>Frontiers in Psychology</i> , <b>2015</b> , 6, 708	3.4	44
141	Emerging drugs in Europe. <i>Current Opinion in Psychiatry</i> , <b>2014</b> , 27, 243-50	4.9	44
140	Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 78, 970-80	3.8	42
139	The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. <i>Journal of Clinical Psychopharmacology</i> , <b>2008</b> , 28, 523-9	1.7	42
138	MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. <i>European Journal of Clinical Pharmacology</i> , <b>2005</b> , 61, 551-4	2.8	42
137	Metabolite profiling of olive oil and thyme phenols after a sustained intake of two phenol-enriched olive oils by humans: Identification of compliance markers. <i>Food Research International</i> , <b>2014</b> , 65, 59-68	7	40
136	Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT). <i>PLoS ONE</i> , <b>2012</b> , 7, e47599	3.7	40
135	The efficacy of cognitive behavioural therapy and advocacy interventions for women who have experienced intimate partner violence: a systematic review and meta-analysis. <i>Annals of Medicine</i> , <b>2014</b> , 46, 567-86	1.5	39
134	Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI). <i>Drug and Alcohol Dependence</i> , <b>1994</b> , 35, 203-9	4.9	38
133	Functional alteration in frontolimbic systems relevant to moral judgment in cocaine-dependent subjects. <i>Addiction Biology</i> , <b>2014</b> , 19, 272-81	4.6	37
132	Efficacy of psychostimulant drugs for amphetamine abuse or dependence. <i>The Cochrane Library</i> , <b>2013</b> , CD009695	5.2	36

131	Effect of olive oil phenolic compounds on the expression of blood pressure-related genes in healthy individuals. <i>European Journal of Nutrition</i> , <b>2017</b> , 56, 663-670	5.2	35
130	Analysis of free hydroxytyrosol in human plasma following the administration of olive oil. <i>Journal of Chromatography A</i> , <b>2016</b> , 1437, 183-190	4.5	35
129	Complementary phenol-enriched olive oil improves HDL characteristics in hypercholesterolemic subjects. A randomized, double-blind, crossover, controlled trial. The VOHF study. <i>Molecular Nutrition and Food Research</i> , <b>2015</b> , 59, 1758-70	5.9	35
128	Analysis of ECs and related compounds in plasma: artifactual isomerization and ex vivo enzymatic generation of 2-MGs. <i>Journal of Lipid Research</i> , <b>2014</b> , 55, 966-77	6.3	35
127	Untargeted metabolomics in doping control: detection of new markers of testosterone misuse by ultrahigh performance liquid chromatography coupled to high-resolution mass spectrometry. <i>Analytical Chemistry</i> , <b>2015</b> , 87, 8373-80	7.8	34
126	Cannabinoids: from pot to lab. <i>International Journal of Medical Sciences</i> , <b>2018</b> , 15, 1286-1295	3.7	34
125	Abuse liability of flunitrazepam among methadone-maintained patients. <i>Psychopharmacology</i> , <b>1998</b> , 140, 486-95	4.7	34
124	Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , <b>2018</b> , 1, e183485	10.4	34
123	Common and distinct neural correlates of facial emotion processing in social anxiety disorder and Williams syndrome: A systematic review and voxel-based meta-analysis of functional resonance imaging studies. <i>Neuropsychologia</i> , <b>2014</b> , 64, 205-17	3.2	32
122	Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. <i>Frontiers in Psychiatry</i> , <b>2019</b> , 10, 943	5	32
121	Drug-related deaths in hospital inpatients: A retrospective cohort study. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 542-552	3.8	32
120	Consumption of new psychoactive substances in a Spanish sample of research chemical users. <i>Human Psychopharmacology</i> , <b>2013</b> , 28, 332-40	2.3	30
119	Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart. <i>Psychopharmacology</i> , <b>2013</b> , 225, 883-93	4.7	30
118	Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, e1113-21	4.6	30
117	Attenuated frontal and sensory inputs to the basal ganglia in cannabis users. <i>Addiction Biology</i> , <b>2017</b> , 22, 1036-1047	4.6	29
116	Modulation of brain structure by catechol-O-methyltransferase Val(158) Met polymorphism in chronic cannabis users. <i>Addiction Biology</i> , <b>2014</b> , 19, 722-32	4.6	29
115	Moderate consumption of wine, through both its phenolic compounds and alcohol content, promotes hydroxytyrosol endogenous generation in humans. A randomized controlled trial. <i>Molecular Nutrition and Food Research</i> , <b>2015</b> , 59, 1213-6	5.9	27
114	Acute Pharmacological Effects of 2C-B in Humans: An Observational Study. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 206	5.6	27

113	Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion. <i>Drug Metabolism and Disposition</i> , <b>2009</b> , 37, 1448-55	4	27
112	Cytokine-induced depression: current status and novel targets for depression therapy. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2014</b> , 13, 1066-74	2.6	27
111	Drug Interactions With New Synthetic Opioids. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1145	5.6	27
110	Urinary profile of methylprednisolone and its metabolites after oral and topical administrations. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2013</b> , 138, 214-21	5.1	25
109	Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. <i>Clinical Pharmacokinetics</i> , <b>2011</b> , 50, 319-29	6.2	24
108	The efficacy of computerized interventions to reduce cannabis use: A systematic review and meta-analysis. <i>Addictive Behaviors</i> , <b>2018</b> , 79, 52-60	4.2	24
107	Memory and mood during MDMA intoxication, with and without memantine pretreatment. <i>Neuropharmacology</i> , <b>2014</b> , 87, 198-205	5.5	23
106	Pharmacokinetics of Mephedrone and Its Metabolites in Human by LC-MS/MS. <i>AAPS Journal</i> , <b>2017</b> , 19, 1767-1778	3.7	23
105	A comparison of the acute behavioral effects of flunitrazepam and triazolam in healthy volunteers. <i>Psychopharmacology</i> , <b>1996</b> , 125, 1-12	4.7	23
104	Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2017</b> , 16, 554-566	2.6	23
103	Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 89-98	4.1	22
102	Putting clinical pharmacology in context: the use of popular movies. <i>Journal of Clinical Pharmacology</i> , <b>2004</b> , 44, 30-6	2.9	22
101	Fast and sensitive UHPLC-MS/MS analysis of cannabinoids and their acid precursors in pharmaceutical preparations of medical cannabis and their metabolites in conventional and non-conventional biological matrices of treated individual. <i>Talanta</i> , <b>2020</b> , 209, 120537	6.2	22
100	Pharmacokinetic Comparison of Soy Isoflavone Extracts in Human Plasma. <i>Journal of Agricultural and Food Chemistry</i> , <b>2015</b> , 63, 6946-53	5.7	21
99	Neurocognitive performance following acute mephedrone administration, with and without alcohol. <i>Journal of Psychopharmacology</i> , <b>2016</b> , 30, 1305-1312	4.6	20
98	Patterns of use and toxicity of new para-halogenated substituted cathinones: 4-CMC (clephedrone), 4-CEC (4-chloroethcatinone) and 4-BMC (brephedrone). <i>Human Psychopharmacology</i> , <b>2017</b> , 32, e2621	2.3	20
97	Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions. <i>BioMed Research International</i> , <b>2015</b> , 2015, 643878	3	20
96	Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart Human pharmacology of MDMA after repeated doses taken 4 h apart. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 1637-49	1.2	19



95	Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH. <i>Clinical Chemistry</i> , <b>2001</b> , 47, 1788-95	5.5	19
94	Detection and characterization of betamethasone metabolites in human urine by LC-MS/MS. <i>Drug Testing and Analysis</i> , <b>2015</b> , 7, 663-72	3.5	18
93	Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2012</b> , 27, 605-13	2.2	18
92	Cross-reactivity of stimulants found in sports drug testing by two fluorescence polarization immunoassays. <i>Journal of Analytical Toxicology</i> , <b>1996</b> , 20, 165-70	2.9	18
91	Determination of Recent Growth Hormone Abuse Using a Single Dried Blood Spot. <i>Clinical Chemistry</i> , <b>2016</b> , 62, 1353-60	5.5	18
90	Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism. <i>Obesity Surgery</i> , <b>2017</b> , 27, 3194-3201	3.7	17
89	Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis. <i>Psychopharmacology</i> , <b>2019</b> , 236, 2677-2685	4.7	17
88	GC-MS Quantification Method for Mephedrone in Plasma and Urine: Application to Human Pharmacokinetics. <i>Journal of Analytical Toxicology</i> , <b>2017</b> , 41, 100-106	2.9	17
87	Functional effects of chronic paroxetine versus placebo on the fear, stress and anxiety brain circuit in Social Anxiety Disorder: initial validation of an imaging protocol for drug discovery. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, 105-16	1.2	17
86	Semantic Verbal Fluency Pattern, Dementia Rating Scores and Adaptive Behavior Correlate With Plasma A $\beta$ 2 Concentrations in Down Syndrome Young Adults. <i>Frontiers in Behavioral Neuroscience</i> , <b>2015</b> , 9, 301	3.5	17
85	Clinical Pharmacology of the Synthetic Cathinone Mephedrone. <i>Current Topics in Behavioral Neurosciences</i> , <b>2017</b> , 32, 313-331	3.4	17
84	Ethanol induces hydroxytyrosol formation in humans. <i>Pharmacological Research</i> , <b>2015</b> , 95-96, 27-33	10.2	16
83	Oral Administration of Cannabis and $\Delta^9$ -tetrahydrocannabinol (THC) Preparations: A Systematic Review. <i>Medicina (Lithuania)</i> , <b>2020</b> , 56,	3.1	16
82	Detection and characterization of triamcinolone acetonide metabolites in human urine by liquid chromatography/tandem mass spectrometry after intramuscular administration. <i>Rapid Communications in Mass Spectrometry</i> , <b>2014</b> , 28, 1829-39	2.2	16
81	Metabolomics predicts the pharmacological profile of new psychoactive substances. <i>Journal of Psychopharmacology</i> , <b>2019</b> , 33, 347-354	4.6	16
80	Inhibition of MDMA-induced increase in cortisol does not prevent acute impairment of verbal memory. <i>British Journal of Pharmacology</i> , <b>2013</b> , 168, 607-17	8.6	15
79	Mephedrone and Alcohol Interactions in Humans. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 1588	5.6	14
78	Sensation seeking amongst healthy volunteers participating in phase I clinical trials. <i>British Journal of Clinical Pharmacology</i> , <b>1995</b> , 39, 405-9	3.8	14

77	Inflammatory mediators and dual depression: Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders. <i>PLoS ONE</i> , <b>2019</b> , 14, e0213791	3.7	13
76	Monitoring nicotine intake from e-cigarettes: measurement of parent drug and metabolites in oral fluid and plasma. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2017</b> , 55, 415-423	5.9	13
75	Dose-Response Pharmacological Study of Mephedrone and Its Metabolites: Pharmacokinetics, Serotonergic Effects, and Impact of CYP2D6 Genetic Variation. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 596-604	6.1	12
74	Evaluation of fibronectin 1 in one dried blood spot and in urine after rhGH treatment. <i>Drug Testing and Analysis</i> , <b>2017</b> , 9, 1011-1016	3.5	12
73	Surviving life-threatening MDMA (3,4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir (RTV). <i>Intensive Care Medicine</i> , <b>2012</b> , 38, 1239-40	14.5	12
72	Genetic and protein biomarkers in blood for the improved detection of GH abuse. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2016</b> , 128, 111-118	3.5	12
71	Potential Use of Ayahuasca in Grief Therapy. <i>Omega: Journal of Death and Dying</i> , <b>2019</b> , 79, 260-285	1.6	12
70	Conditioned Subjective Responses to Socially Relevant Stimuli in Social Anxiety Disorder and Subclinical Social Anxiety. <i>Clinical Psychology and Psychotherapy</i> , <b>2015</b> , 22, 221-31	2.9	11
69	Key interindividual determinants in MDMA pharmacodynamics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 183-195	5.5	11
68	3,4-methylenedioxymethamphetamine induces gene expression changes in rats related to serotonergic and dopaminergic systems, but not to neurotoxicity. <i>Neurotoxicity Research</i> , <b>2014</b> , 25, 161-9	4.3	11
67	Facial emotion processing in patients with social anxiety disorder and Williams-Beuren syndrome: an fMRI study. <i>Journal of Psychiatry and Neuroscience</i> , <b>2016</b> , 41, 182-91	4.5	11
66	MDMA interactions with pharmaceuticals and drugs of abuse. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2020</b> , 16, 357-369	5.5	10
65	The definition of placebo in the informed consent forms of clinical trials. <i>PLoS ONE</i> , <b>2014</b> , 9, e113654	3.7	10
64	Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity. <i>Scientific Reports</i> , <b>2019</b> , 9, 20405	4.9	10
63	UHPLC-MS/MS analysis of cannabidiol metabolites in serum and urine samples. Application to an individual treated with medical cannabis. <i>Talanta</i> , <b>2021</b> , 223, 121772	6.2	10
62	Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake. <i>Psychopharmacology</i> , <b>2015</b> , 232, 1921-9	4.7	9
61	LC-MS/MS method for the quantification of new psychoactive substances and evaluation of their urinary detection in humans for doping control analysis. <i>Drug Testing and Analysis</i> , <b>2020</b> , 12, 785-797	3.5	9
60	Effects of cannabis exposure in the prenatal and adolescent periods: Preclinical and clinical studies in both sexes. <i>Frontiers in Neuroendocrinology</i> , <b>2020</b> , 57, 100841	8.9	9



59	Determination of free serotonin and its metabolite 5-HIAA in blood human samples with consideration to pre-analytical factors. <i>Biomedical Chromatography</i> , <b>2014</b> , 28, 1641-6	1.7	9
58	A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome. <i>Clinical Nutrition</i> , <b>2020</b> , 39, 378-387	5.9	9
57	Quality of Life, Mental Health, Personality and Patterns of Use in Self-Medicated Cannabis Users with Chronic Diseases: A 12-Month Longitudinal Study. <i>Phytotherapy Research</i> , <b>2020</b> , 34, 1670-1677	6.7	8
56	ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, 420-4	1.2	8
55	UHPLC-HRMS and GC-MS Screening of a Selection of Synthetic Cannabinoids and Metabolites in Urine of Consumers. <i>Medicina (Lithuania)</i> , <b>2020</b> , 56,	3.1	8
54	Acute Effects of 2C-E in Humans: An Observational Study. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 233	5.6	7
53	Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter. <i>Scientific Reports</i> , <b>2018</b> , 8, 1061	4.9	7
52	Ultra-High Performance Liquid Chromatography-High Resolution Mass Spectrometry and High-Sensitivity Gas Chromatography-Mass Spectrometry Screening of Classic Drugs and New Psychoactive Substances and Metabolites in Urine of Consumers. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	7
51	High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial.. <i>Lancet Respiratory Medicine</i> , <b>2022</b> ,	35.1	6
50	Concurrent Use of Cannabis and Alcohol: Neuropsychiatric Effect Consequences. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2017</b> , 16, 592-597	2.6	6
49	Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	6
48	Fit-for-Purpose Radio Receptor Assay for the Determination of Growth Hormone Secretagogues in Urine. <i>Journal of Biomolecular Screening</i> , <b>2015</b> , 20, 1268-76		5
47	Non-Linear Formation of EtG and FAEs after Controlled Administration of Low to Moderate Doses of Ethanol. <i>Alcohol and Alcoholism</i> , <b>2017</b> , 52, 587-594	3.5	5
46	In vitro study of the apical microleakage with resilon root canal filling using different final endodontic irrigants. <i>Journal of Clinical and Experimental Dentistry</i> , <b>2015</b> , 7, e212-7	1.4	5
45	Study of paracetamol 1-g oral solution bioavailability. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , <b>2008</b> , 30, 37-41		5
44	Disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis. <i>Phytotherapy Research</i> , <b>2021</b> , 35, 1646-1657	6.7	5
43	Acute Pharmacological Effects of Oral and Intranasal Mephedrone: An Observational Study in Humans. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	5
42	On-site testing of 3,4-methylenedioxymethamphetamine (ecstasy) in saliva with Drugwipe and Drugread: a controlled study in recreational users. <i>Clinical Chemistry</i> , <b>2002</b> , 48, 174-6	5.5	5

41	Cannabis as Secondary Drug Is Not Associated With a Greater Risk of Death in Patients With Opiate, Cocaine, or Alcohol Dependence. <i>Journal of Addiction Medicine</i> , <b>2017</b> , 11, 34-39	3.8	4
40	A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-Imidazoline Receptor). <i>Frontiers in Psychiatry</i> , <b>2017</b> , 8, 258	5	4
39	Bioethical principles, clinical research and popular movies. <i>Medical Education</i> , <b>2013</b> , 47, 1141-2	3.7	4
38	Determination of the Synthetic Cannabinoids JWH-122, JWH-210, UR-144 in Oral Fluid of Consumers by GC-MS and Quantification of Parent Compounds and Metabolites by UHPLC-MS/MS. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	4
37	The Tryptophan System in Cocaine-Induced Depression. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	4
36	Acute Pharmacological Effects and Oral Fluid Biomarkers of the Synthetic Cannabinoid UR-144 and THC in Recreational Users. <i>Biology</i> , <b>2021</b> , 10,	4.9	4
35	Alcohol Consumption during Pregnancy: Analysis of Two Direct Metabolites of Ethanol in Meconium. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17, 417	6.3	4
34	Soy Isoflavone Extract Does Not Increase the Intoxicating Effects of Acute Alcohol Ingestion in Human Volunteers. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 131	5.6	3
33	Ethics in clinical research: Contributions of the new version of the Council for International Organizations of Medical Sciences guidelines. <i>Medicina Clínica</i> , <b>2018</b> , 150, 282-285	1	3
32	Disposition of Cannabidiol Metabolites in Serum and Urine from Healthy Individuals Treated with Pharmaceutical Preparations of Medical Cannabis. <i>Pharmaceuticals</i> , <b>2020</b> , 13,	5.2	3
31	Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder?. <i>Drug and Alcohol Dependence</i> , <b>2018</b> , 188, 180-186	4.9	3
30	A Comparison of Acute Pharmacological Effects of Methylenedioxymethamphetamine (MDMA) Administration in Humans and Oral Fluid Concentrations as Biomarkers of Exposure. <i>Biology</i> , <b>2021</b> , 10,	4.9	3
29	Interaction of Energy Drinks with Prescription Medication and Drugs of Abuse. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	3
28	Addiction to Hallucinogens, Dissociatives, Designer Drugs and Legal Highs. <i>Pharmaceuticals</i> , <b>2015</b> , 567-596		2
27	Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 708372	5.7	2
26	The synthetic cannabinoids: JWH, four years of analysis. <i>European Psychiatry</i> , <b>2016</b> , 33, S115-S116	6	2
25	Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication. <i>Psychopharmacology</i> , <b>2018</b> , 235, 709-717	4.7	2
24	Abuse Potential of Cathinones in Humans: A Systematic Review.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,	5.1	2

23	Blakkañan Emerging Trend Or a Mass Media Phenomenon? Presence of alpha-pvp in Samples Submitted To a Drug Checking Facility. <i>European Psychiatry</i> , <b>2016</b> , 33, S442-S442	6	1
22	Addiction of Hallucinogens, Dissociatives, Designer Drugs and Illegal Highs Update on Potential Therapeutic Use <b>2021</b> , 259-279		1
21	Patients with alcohol use disorder: initial results from a prospective multicenter registry in the Spanish Network on Addiction Disorders. CohRTA Study. <i>Revista De Psicologia De La Salud</i> , <b>2018</b> , 30, 292-300	1	
20	PCP analogues in samples of Barcelona from 2009 to 2015. <i>European Psychiatry</i> , <b>2016</b> , 33, S117-S117	6	1
19	Analysis of the effectiveness of second oral glucose-lowering therapy in routine clinical practice from the mediterranean area: A retrospective cohort study. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 171, 108616	7.4	1
18	Long-Term Outcomes of Patients With Cocaine Use Disorder: A 18-years Addiction Cohort Study. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 625610	5.6	1
17	Drug-Related Deaths in a Tertiary Hospital: Characteristics of Spontaneously Reported Cases and Comparison to Cases Detected from a Retrospective Study. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
16	New Synthetic Opioids Use among Patients in Treatment for an Opioid Use Disorder in Barcelona.. <i>European Addiction Research</i> , <b>2022</b> , 1-8	4.6	1
15	Ethics in clinical research: Contributions of the new version of the Council for International Organizations of Medical Sciences guidelines. <i>Medicina Clínica (English Edition)</i> , <b>2018</b> , 150, 282-285	0.3	0
14	Daidzein modulates cocaine-reinforcing effects and cue-induced cocaine reinstatement in CD-1 male mice. <i>Psychopharmacology</i> , <b>2021</b> , 238, 1923-1936	4.7	0
13	Acute Pharmacological Effects and Oral Fluid Concentrations of the Synthetic Cannabinoids JWH-122 and JWH-210 in Humans After Self-Administration: An Observational Study. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 705643	5.6	0
12	Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder. <i>Biomedicines</i> , <b>2022</b> , 10, 947	4.8	0
11	New Psychoactive Substances Consumption in Opioid-Use Disorder Patients. <i>Biology</i> , <b>2022</b> , 11, 645	4.9	0
10	Meconium Biomarkers of Prenatal Alcohol Exposure <b>2019</b> , 585-594		
9	Reply. <i>Medicina Clínica</i> , <b>2019</b> , 152, 79-80	1	
8	Answer to the Letter to the Editor Concerning "Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism". <i>Obesity Surgery</i> , <b>2017</b> , 27, 3006-3007	3.7	
7	Corrigendum to "Genetic and protein biomarkers in blood for the improved detection of GH abuse" [J. Pharm. Biomed. Anal. 128 (2016) 111-118, doi: 10.1016/j.jpba.2016.05.022.]. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2017</b> , 134, 385	3.5	
6	Author's response to the Letter to the Editor of Tfelt-Hansen. <i>European Journal of Clinical Pharmacology</i> , <b>2011</b> , 67, 645-646	2.8	

- 5 Nocebo Response in Attention Deficit Hyperactivity Disorder: Meta-Analysis and Meta-Regression of 105 Randomized Clinical Trials.. *Journal of Attention Disorders*, **2022**, 10870547221075845 3.7
- 4 Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses. *Arzneimittelforschung*, **1997**, 47, 528-30
- 3 Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration. *Methods and Findings in Experimental and Clinical Pharmacology*, **1997**, 19, 343-50
- 2 Drug and MDMA Interactions Implications for Public Health **2022**, 1-26
- 1 BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression.. *Frontiers in Psychiatry*, **2022**, 13, 836771 5